ReadYourDNA

Lonsurf

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Lonsurf

What it is

Lonsurf is an oral chemotherapy combining trifluridine, a nucleoside analogue that is built into DNA and disrupts it, with tipiracil, which blocks thymidine phosphorylase, the enzyme that would otherwise break trifluridine down quickly. It is used for advanced bowel and stomach cancers after other treatments, alone or with bevacizumab.

How genes come into it

Trifluridine enters cells partly through the nucleoside transporter SLC29A1, and tipiracil is cleared by the kidneys with the help of SLC22A2 and SLC47A1. The gene studies on this page, from a small number of studies, looked at these transporter genes for how well treatment worked. There is no CPIC or DPWG guideline.

What research found

Every published finding on gene variants and Lonsurf. Upload your DNA file to see which of these rows apply to you.

Rated evidence (2 rated variants)

PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.

SLC29A1 rs9394992: Level 3. Efficacy: Colorectal Neoplasms. 1.

SLC29A1 rs760370: Level 3. Efficacy: Colorectal Neoplasms. 1.

Response (4 findings)

Studies of how well it worked in people carrying a variant.

SLC29A1 rs760370: Genotypes AG + GG is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype AA.

SLC29A1 rs9394992: Genotypes CT + TT is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype CC.

SLC22A2 rs316019: Allele A is not associated with response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to allele C.

SLC47A1 rs2289669: Allele A is not associated with response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to allele G.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

5-FU (Antimetabolites)

Alimta (Antimetabolites)

Cytosar-U (Antimetabolites)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com